Catalogue of Ultram.

Trade name of Ultram of TRAMADOL HYDROCHLORATE

CATEGORIES, MARKS, FORMS And COST OF The THERAPY

CATEGORIES: Analgesias; Antipyretics; Agents Of The Central Nervous System; The FDA Aprobo' 1995 Marches; The FDA Clasifica 1S ("Standard Revision"); Agonists Of The Nacrótico (Controlled); Pain

MARKS: Ultram

DESCRIPTION

Ultram (hydrochlorate of tramadol) is centrally analgesic to act. The chemical well-known for hydrochlorate of tramadol is (clorhidrato)cis-2-[(dimethylamino)methyl]-1-(3-)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl of cyclohexanol.

The molecular weight of hydrochlorate of tramadol is 299.8. The hydrochlorate of Tramadol is a dust of the target, bitter, crystalline and odorless. He is easily soluble in water and ethanol and has pKa of 9.41. The coefficient of the partition of water/n-octanol is 1,35 in pH 7. The tablets of Ultram contain magnesium 50 of hydrochlorate of tramadol and are white in color. The inactive ingredients in the tablet are maize starch, methylcellulose hydroxypropyl, lactose, estearato of magnesium, microcrystalline cellulose, polyethylene glycol, polysorbate 80, dioxide of glycolate of the starch of sodium, titanium and wax.

CLINICAL PHARMACOLOGY

Pharmacodynamics Ultram is a synthetic analgesic compound centrally that acts that drift of natural sources nor chemically has not been related to the nacróticos. Although its way of the action is not totally understood of the tests animals, at least two complementary mechanisms appear applicable; tying to the receivers of - opioid and inhibition of reuptake of norepinephrine and serotonin. The activity of opioid of Ultram derives from the obstacle under the affinity of the compound of the father to the receivers of - opioid and a higher obstacle of the affinity from metabolite M1. In the models animals, M1 is up to 6 times more powerful than tramadol in producing more powerful analgesia and 200 times in the obstacle of - opioid. The contribution to the human analgesia of tramadol M1 in relation to is not known.

antinociception Tramadol-induced is put in against only partially by naloxone of the nacrótico in several tests animals. In addition, tramadol has been demonstrated to inhibit reuptake of norepinephrine and serotonin in vitro, as they have some other analgesias of opioid. These last mechanisms can contribute independently to total the analgesic profile of Ultram. The beginning of the analgesia in human beings is evident in the term of one hour after administration and reaches a tip on approximately two to three hours of maximum concentrations of the plasma is reached near two hours after the administration, that the corelative ones close by with the time hoisting the relevación of the pain.

Aside from analgesia, the administration of Ultram can produce a constellation of symptoms (vertigos including, somnolencia, nausea, constipation, sweating and prurito) similar to the one of opioid. Nevertheless, tramadol causes the depression less respiratory perceivably than morphine. In contrast to morphine, tramadol has not been demonstrated to the launching of the histamina of the cause. In the therapeutic doses, Ultram does not have any effect in heart rate, the left-ventricular function or the index cardiac. The changes orthostatic in the arterial pressure have been observed.

Absorption Of the Pharmacokinetics: Tramadol racémico is absorbed quickly and almost totally after the oral administration. The bad absolute biodisponibilidad of an oral dose of magnesium 100 is approximately 75%. The oral administration of Ultram with the food perceivably does not affect its index or degree of the absorption. Therefore, Ultram can be administered without consideration some towards the food (.) Maxima the bad concentration of plasma SD of tramadol racémico is 308. 78 ng/ml and happen in approximately two hours after a single oral dose of magnesium 100 in healthy subjects. In this dose Maxima the bad concentration of the plasma of the active monkey-Or-desmethyl metabolite, racémico M1 is 55. 20 ng/ml and happen approximately three hours of post-dose. Separated [ + ] - and [ - ]-]-enantiomers of tramadol follow generally a parallel course of the time in plasma after a single oral dose of magnesium 100 of Ultram. After the oral administration of magnesium the 100 of tramadol maximum concentrations of the plasma of [ - ]-]-enantiomer of tramadol is something lower than those of [ to +]-enantiomer (148, 33 against. 168. 36 ng/ml respectively). [ - enantiomer ]-M1 is present in concentrations slightly more discharges of the plasma that [ enantiomer +]-M1 (35, 10 against. 26. 13 ng/ml respectively). In the constant state that followed 100 a regime of magnesium q.i.d. of tramadol, 3 of 18 subjects formed relatively low amounts of [ +]-M1, whereas his [ - the formation ]-M1 continued being similar to the one of other subjects. This is created not to be clinical significant.

The concentrations of the plasma of tramadol racémico are trustworthy on a magnesium 50 to range single-dose of magnesium 100. This one is also conditions of several true inferior doses. The constant state is reached after two days of Ultram of metering percent a regime of magnesium q.i.d. (the Maxima concentration of the plasma was 592. 177 ng/ml). The period of the plasma of tramadol after a single metering and multiple era 6 and 7 hours, respectively. This increase in period on the multiple metering is not considered to be clinical significant or to authorize the adjustment of the metering for the chronic use.

Racémico Tramadol of the bad plasma and racémicos profiles of the M1 concentration-against-time that daily follow a single oral dose of magnesium 100 of Ultram and after twenty-nine 100 doses of magnesium four times.

Distribution: The volume of 2,9 distribution of tramadol was 2,6 and liters/kg in respectively following the masculine and feminine subjects a dose of the intravenous one of magnesium 100. The obstacle of tramadol to human proteins of the plasma is approximately 20% and also tying appears to be independent of the concentration until g/ml 10. The saturation of the obstacle of the protein of the plasma only happens in the concentrations outside excellent clinical range. Although it is not confirmed in human beings, tramadol has been demonstrated in rats to cross the barrier blood-brain.

Metabolism: Metaboliza Tramadol extensively after the oral administration. Approximately 30% of the dose are excreted in tinkles it like drug without changes, whereas 60% of the dose are excreted like metabolites. The rest is excreted or like not identified or metabolites unextractable. Main the metabolic ways appear to be n and O-demethylation and glucuronidation or sulfatación in the liver. Only metabolite (denoted M1 monkey-Or-desmethyltramadol) is farmacológico assets. The production of M1 is employee in isoenzima CYP2D6 of cytochrome P-450.

Elimination: The bad terminal periods of the elimination of the plasma of tramadol racémico and racémico M1 are 6.3. 1.4 and 7.4. 1,4 hours respectively. The period of the elimination of the plasma of tramadol racémico increased as of approximately six hours to seven hours on the multiple metering.

Special Populations: Renal: Renales results deteriorated of the function in an index and a degree diminished of the excreción of tramadol and his metabolite active M1. In patients with separations of the creatinina of the adjustment less of those of 30/ml/min of the metering regime it is recommended (the METERING and the ADMINISTRATION see). Cleared the total amount of tramadol and M1 during a period of the dialysis is less of 7% of the dose of the administrator.

Hepático: The metabolism of tramadol and M1 is reduced in patients with the cirrhosis outpost of the liver giving by result a greater area under serum-concentration-against-time to curve tramadol and longer periods of tramadol and the M1 elimination (13 hours for tramadol and 19 hours for M1). In patients cirrhotic the adjustment of the metering regime is recommended (the METERING and the ADMINISTRATION see).

Age: The healthy greater subjects aged 65 to 75 years less have concentrations of tramadol of the plasma and comparable periods of the elimination to those observed in healthy subjects than 65 years of the age. In subjects on 75 years of maximum concentrations of the serum 208 rise slightly (against. 162 ng/ml) and the period of the elimination extends (7 slightly against. 6 hours) compared to subjects 65 to 75 years of the age. The adjustment of the daily dose is recommended for the patients oldest of 75 years (the METERING and the ADMINISTRATION see).

Sort: The absolute biodisponibilidad of tramadol was 73% in men and 79% in females. The separation of the plasma was 6,4 ml/min/kg in men and 5,7 ml/min/kg in the females that followed a 100 dose of magnesium IV of tramadol. After a single oral dose, and fitting according to corporal weight, the females had a Maxima concentration 12% more discharge of tramadol and an area 35% more discharge underneath the curve of the concentration-time compared the men. This difference can not be of any clinical meaning.

Clinical Studies: Ultram (hydrochlorate of tramadol) has occurred in single oral doses of magnesium 50, 75, 100, 150 and 200 to the patients with pain after the surgical section the procedures (ortopédico, gynecological, cesariano) and the pain that the surgery followed oral (affected tooth extraction).

In the models single-dose del pain that followed surgery oral, the relevación del pain was demonstrated in some patients in the doses magnesium 50 del magnesium and 75. A dose 100 of the Ultram magnesium tended to provide to superior of the analgesia to magnesium of sulphate 60 of codeine, but he was not effective like the combination of magnesium of aspirin 650 with magnesium of phosphate 60 of codeine. In models single-dose of the pain after surgical procedures, 150 that the magnesium provided the generally comparable analgesia to the combination of acetaminophen magnesium 650 with magnesium of napsylate 100 of propoxyphene, with a tendency towards a last maximum effect.

Ultram (hydrochlorate del tramadol) has studied in three controlled tests to long term that implied to a total of 820 patients with 530 patients who received Ultram. The patients with chronic conditions such as backache ortopédicas and common under, cancer, pain neuropathic and conditions incorporated a phase double-blind of an a three months. The daily doses of the average of magnesium the approximately 250 of Ultram in the produced analgesia doses divided comparable with five doses of acetaminophen the magnesium the 300 with magnesium of phosphate 30 of codeine (Tylenol. with codeine # 3) doses of newspaper five of magnesium of aspirin 325 with the newspaper of magnesium of phosphate 30 of codeine and with two to three doses of they acetaminophen magnesium 500 with magnesium of hydrochlorate 5 of oxycodone (Tylox.) newspaper. After the period double-blind, some patients took Ultram in a period opened by up to two years.

INDICATIONS

Ultram is indicated for the management of moderate to the severe moderate pain.

CONTRAINDICATION

Ultram is not due to administer to the patients who have previously demonstrated hypersensitivity to tramadol or in cases of the acute poisoning with alcohol, the hypnosis, analgesias centrally which they acted, opioids or drugs psychotropic.

WARNING

The Tramadol risk of the grasping causes to graspings in the models animals, and some graspings have disclosed in the human beings who received the single excessive oral doses (magnesium 700) or the great intravenous doses (magnesium 300). The administration of Ultram can heighten the risk of the grasping in the patients who take inhibitors from MAO, neuroleptics, other drugs that reduce to patients of the threshold of the grasping with epilepsy, or to patients of another way in the increasing risk for the grasping. Of the studies animals, the administration of naloxone increased the risk of convulsions.

The use with depressing the Ultram of the CNS is due to use with the precaution and in reduced meterings when it is administered to the patients who receive depressing from the CNS such as the alcohol, opioids, anesthetic agents, phenothiazines, tranquilizers or sedative hypnosis.

The use with MAO the Ultram inhibitors is due to use with the great precaution in the patients who take inhibitors from oxidized of monoamine, since tramadol inhibits uptake of norepinephrine and serotonin.

PRECAUTIONS

The respiratory depression when the great doses of Ultram administer with anesthetic medications or the alcohol, respiratory depression can be. The cases of the respiratory depression intraoperative, generally with the great intravenous doses of tramadol and with the concurrent administration of depressing respiratory, have been disclosed in foreign experience. Such boxes are due to treat as overdose (it see SOBREDOSIFICACIÓN). Ultram is due to administer cautiously in patients in the risk for the respiratory depression.

The intracraneal trauma increasing Ultram of the pressure or the head is due to use with the precaution in patients with the pressure or the injury in the increasing intracraneal head. The changes of Pupillary (miosis) of tramadol can darken the existence, the degree or the course of the intracraneal pathology. The clinical ones must also maintain a high index of the mistrust for the adverse reaction of the drug when evaluating mental state in these patients if they are receiving Ultram.

The acute abdominal conditions the administration of Ultram can complicate the clinical burden of patients with acute abdominal conditions.

Employees in Opioids Ultram for the patients physically do not recommend the patients who are employees in opioids. The patients who have recently taken substantial amounts from opioids can experience symptoms of the retirement. Due to the difficulty in the determination of dependency in the patients who have previously received substantial amounts of medication of opioid, the precaution is due to use in the administration of Ultram such patients.

The use in renal and hepática disease deteriorated to renales results of the function in an index and a degree diminished of the excreción of tramadol and his metabolite active M1. In patients with separations of the creatinina of less than 30 ml/min recommends the metering reduction (the METERING and the ADMINISTRATION see).

The metabolism of tramadol and M1 is reduced in patients with the cirrhosis outpost of the liver. In patients cirrhotic, recommends the metering of the reduction (the METERING and the ADMINISTRATION see).

With the period prolonged in these conditions, the profit of the constant state is delayed, so that it can take several days so that the elevated concentrations of the plasma become.

The information for the patients of the patients who are dealt with Ultram must receive the following information:

Ultram can deteriorate the mental or physical capacities required for the operation of potentially dangerous tasks such as to drive a car or operation of the machinery.

The carcinogénesis, mutagénesis, weakening of the Tramadol fertility were not mutágena in the following analyses: The microsomal test of the activation of salmonelas of You love, analysis of the mammalian cell of CHO/HPRT, analysis of linfoma of the mouse (in absence of the metabolic activation), mortal mutation dominant test in mice, test of the Chinese aberration of chromosome in hámsteres, and tests of micronucleus of the marrow in Chinese mice and hámsteres. The mutágenos results happened weak in the presence of the metabolic activation in the analysis of linfoma of the mouse and the test of micronucleus in rats. Total, the weight of evidence of these tests indicates that tramadol does not raise a genotóxico risk to the human beings.

Slight, but statistical a significant one, the increase in two common tumors murine, pulmonary and hepático, were observed in a study of carcinogenicity of the mouse, particularly in the aged mice (that they dose oral up to 30 mg/kg by approximately two years, although the study was not done with the tolerance dose Maxima). This that finds not creates to suggest risk in human beings. No so to find it happened in a study of carcinogenicity of the tariff.

It was not observed any effects on fertility for tramadol in the levels of oral doses up to 50 mg/kg in masculine rats and 75 mg/kg in feminine rats.

Teratogenic Effects: The use in category C of the pregnancy of the pregnancy is not no suitable and well-controlled study in pregnant women there. Ultram is due to only use during pregnancy if the potential advantage justifies the potential risk to the fetus.

Tramadol has demonstrated to be embriotóxico and fetotoxic in mice, the rats and the rabbits and the toxic maternal doses the 3 to 15 times higher human dose Maxima or (120 mg/kg in mice, 25 mg/kg or higher in higher rats and 75 mg/kg or in rabbits), but was not teratogenic in these levels of dose. Any damage to the fetus due to tramadol in the doses was not considered that were not maternal toxic.

Teratogenic in the lineage of mice, rats or rabbits dealt with tramadol was not observed any drug-related effects by the several routes (up to 140 mg/kg for the mice, 80 mg/kg for rats or 300 mg/kg for the rabbits). The embryo and the fetal toxicity consisted mainly of diminished fetal weights, the skeletal osificación and ribs increasing supemumerary in the toxic levels of maternal dose. The passer-by delays in of development or the parameters of the behavior also were considered in small dogs in the prey of rat allowed to give. The embryo and fetal mortality were only disclosed in a study in 300 mg/kg, a dose of the rabbit that would cause extreme maternal toxicity in the rabbit.

In the studies of peri- and postbirthdays in rats, the lineage of prey that received the levels of oral doses (of gavage) of 50 mg/kg or greater had diminished weights, and the survival of the small dog was diminished early in the lactancia in 80 mg/kg (the 6 to 10 times human dose Maxima). Any toxicity for the lineage of prey was not observed that received 8, 10, 20, 25 or 40 mg/kg. The maternal toxicity was observed in all the levels of dose, but the effects on lineage were evident only in the levels of one more a higher dose where the maternal toxicity was more severe.

The work and the Ultram delivery are not due to use before in pregnant women or during of the work unless the potential advantages compensate the risks, because the safe use in pregnancy has not settled down. Tramadol has been demonstrated to cross the placenta. The bad quotient of tramadol of the serum in the umbilical veins compared to the maternales veins era 0,83 for 40 women given tramadol during work.

The effect of Ultram, if there is it, in the last growth, the development, and the functional maturation of the boy is not known.

The care of the Ultram mothers does not recommend for the obstetrical medication preoperative or for the analgesia of post-it gives in mothers of the nurse office because its security in infants and new born has not studied. After a single dose of magnesium 100 of tramadol, the cumulative excreción in maternal milk in the term of 16 hours of postdose was g 100 the g of tramadol (0,1% of the maternal dose) and 27 of M1.

The pediátrico use the pediátrico use of Ultram (hydrochlorate of tramadol) is not recommended because the security and the effectiveness in patients under 16 years of the age have not settled down.

The use in the old ones in subjects on the age of 75 years, concentrations of the serum rises slightly and the period of the elimination rises slightly and the period of the elimination extends slightly. Also aged it is possible to be hoped to vary more extensively in his capacity to tolerate adverse effects of the drug. The daily doses in the excess of magnesium 300 are not recommended in patients on 75 (the METERING and the ADMINISTRATION see).

INTERACTION OF THE DRUG

Tramadol does not appear to induce its own metabolism in human beings, since the observed maximum concentrations of the plasma after the multiple oral doses are higher than hoped based on data single-dose. Tramadol is a smooth inducer of the selected ways of the measured metabolism of the animal drug.

The concomitante administration of Ultram (hydrochlorate of tramadol) with carbamazepine causes a significant increase in metabolism of tramadol, probably with the metabolic induction by carbamazepine. The patients who receive the chronic doses of carbamazepine of the newspaper of magnesium up to 800 can require twice until the recommended dose of Ultram.

Tramadol is metabolizado to M1 by isoenzima of CYP2D6 P-450. Quinidine is a selective inhibitor of that isoenzima; so that the concomitante administration of quinidine and Ultram gives rise to increasing concentrations of tramadol and to reduced concentrations of M1. The clinical consequences of this effect have not been investigated completely, and the effect on concentrations of quinidine is not known.

The concomitante administration of Ultram with cimetidine does not give rise to significant changes clinical in pharmacokinetics of tramadol. Therefore, any alteration of the regime of metering of Ultram is not recommended.

The interactions with inhibitors of MAO due to interference with the mechanisms of the chemical decontamination, have been disclosed for some drugs centrally that acted (the WARNINGS see).

ADVERSE REACTIONS:

Ultram was administered to 550 patients during the periods double-blind or open-label of the extension in the studies of the United States of the chronic pain nonmalignant. Of these patients, 375 were 65 years old or of older. TABLE 1 discloses the cumulative index of the incidence of adverse reactions by 7, 30 and 90 days for the most frequent reactions (5% or more by 7 days). Possible more the frequently disclosed events were in the central nervous system and the gastrointestinal system. Although the reactions enumerated in the table feel to be probably related to the administration of Ultram, the tariffs also disclosed include some events that could have been due to the underlying disease or to the concomitante medication. The total indices of the incidence of adverse experiences in these tests were similar for Ultram and the active control groups, Tylenol with codeine #3 (acetaminophen magnesium 300 with magnesium of phosphate 30 of codeine), and magnesium of aspirin 325 with magnesium of phosphate 30 of codeine. (TABLE 1)

Table 1 - Adverse Tramadol HCl, Reactions

Cumulative incidence of the adverse reactions for Ultram (tramadol HCl)

In chronic tests of the pain Nonmalignant

Up to 7 days up to 30 days up to 90 days

Dizziness/Vertigo 26% 31% 33%

Nausea 24% 34% 40%

Constipation 24% 38% 46%

Headache 18% 26% 32%

Somnolencia 16% 23% 25%

To vomit 9% 13% 17%

Prurito 8% 10% 11%

"Stimulus" 7% 11% 14% of the Cns

Asthenia 6% 11% 12%

To sweat 6% 7% 9%

Dispepsia 5% 9% 13%

Mouth Dries 5% 9% 10%

Diarrea 5% 6% 10%

1 "stimulus of the CNS" is a compound of the nervousness, anxiety, agitation,

tremor, spasticity, emotional euphoria, lability and hallucinations.

Incidence except the one of possibly occasional related 5%: Adverse reactions of the lists of TABLE 2 that happened with an incidence of except the one of 5% in clinical tests, and for which the possibility of an occasional relation with Ultram exists. The reactions separate according to if the incidence were greater of 1%. (TABLE 2)

Table 2 - Adverse Tramadol HCl, Reactions

Possibly Adverse Reactions Related De Ultram

with an incidence of except the one of 5%

Incidence of the adverse reaction

System of the body from 1% to < 5% except the one of 1%

Allergic reaction of the Malaise of the body in its totality;

Accidental injury;

Loss of the weight

Cardiovascular Síncope Of the Vasodilatación; Orthostatic

hypotension; Tachycardia

Anxiety Of The Central Nervous System; Confusion; Grasping (the WARNINGS see);

Paresthesia Coordination; Cognoscitivo

disturbance; disfunción;

Euphoria; Nervous Hallucinations; Tremor;

ness; Amnesia of dis- of the dream; Difficulty inside

concentration of the order; Abnormal

step

Gastrointestinal abdominal pain;

Anorexy; Flatulencia

Hipertonía De Musculoskeletal

Respiratory Dyspnea

Eruption De Piel Urticaria, Vesicles

Visual Disgeusia of the disturbance of the special senses

Urogenital urinary retention; Disuria; Menstrual Dis-

Urinary frequency; order

Symptoms of Menopausal

Other adverse experiences, indetermine occasional relation: A variety of other adverse events was disclosed infrequently in the patients who took Ultram during clinical tests. An occasional relation between Ultram and these events has not been determined. Nevertheless, the most significant events are enumerated down like alerting the information to the doctor.

Body in its totality: Suicidal tendency.

Cardiovascular: Abnormal ECG, hypertension, isquemia of the myocardium, palpitaciones.

Central Nervous System: Jaqueca

Gastrointestinal: Gastrointestinal drain, hepatitis, estomatitis.

Abnormalitys of the laboratory: Increase of the creatinina, elevated enzymes of the liver, diminution of the hemoglobina, proteinuria.

Sensorial: Cataracts, deafness, humming.

ABUSE And DEPENDENCY OF The DRUG

Although tramadol can produce the drug dependency of the type of - opioid (as codeine or dextropropoxyphene) and potentially can be abused, has been little evidence of the abuse in foreign clinical experience. In clinical tests, tramadol produced carries out similar to opioid, and in the doses supratherapeutic was recognized as opioid in subjective/behavioral studies. The development of the tolerance has disclosed to be relatively smooth and retirement when the present, it is not considered to be as severe as that one produced by others opioids. Part of the activity and a certain extension of tramadol of the duration of the activity of - opioid. The activity delayed of - opioid is created to reduce the responsibility of the abuse of a drug.

An analysis for tramadol is not included in the routine screens of tinkles it for drugs of the abuse.

SOBREDOSIFICACIÓN:

Few boxes of overdose with tramadol have been disclosed. The estimations of the dose ingested in foreign fatalities have been in the range from 3 to 5 g. 3 an intentional overdose of g in a patient in the clinical studies produced emesis and no sequelae. The lowest dose disclosed to be associated to a fatality was possibly between magnesium 500 and 1000 in a woman of 40 kilograms, but the details of the case are not known totally.

The serious potential consequences of the sobremetering are respiratory depression and grasping. Naloxone will invest some, but all the symptoms caused by the sobremetering with Ultram not to recommend the treatment of general support. The primary attention is due to give the securing of the suitable respiratory interchange. One does not hope that the hemodialisis is beneficial because exempt only a small percentage of the administered dose. The convulsions that happened in the mice that followed the administration of toxic doses of tramadol could be suppressed with barbiturates or benzodiazepines, but were increased with naloxone. Naloxone did not change the mortality of an overdose in mice.

METERING And ADMINISTRATION

For the treatment of painful magnesium 50 of Ultram of the conditions (hydrochlorate of tramadol) to magnesium 100 it can be administered according to needed by the relevación the each four to six hours, not to exceed magnesium 400 per day. For moderate Ultram 50 of the pain the magnesium can be adapted like the initial dose, and for a more severe Ultram 100 of the pain the magnesium is generally more effective like the initial dose.

The individualización of the data available of the dose does not suggest an adjustment of the metering is necessary in greater patients 65 to 75 years of the age unless also they have renal or hepática weakening. For patients the greater on 75 years of old not more than 300 mg/day in divided doses as above it is recommended. In all the patients with the separation of the creatina less than 30 ml/min, is recommended that the interval of metering of Ultram is lengthened to 12 hours with a dose of the maximum daily of magnesium 200. Since only 7% of an administered dose are cleared by the hemodialisis, the dialysis patients can receive their regular dose in the day of the dialysis. The dose recommended for the patients with cirrhosis is the magnesium 50 every 12 hours. The patients who receive carbamazepine chronic dose up to 800 that the newspaper of magnesium requires twice until the recommended dose of Ultram.

HOW HE IS PROVIDED

The tablet of magnesium 50 (white, capsule-formed tablet film-had) recorded "McNeil" in a side and "659" of Ultram (hydrochlorate of tramadol) in the other side.

Tablet of magnesium 50 of Ultram (hydrochlorate of tramadol) - bottles of NDC 0045-0659 of 100 tablets, and packages of 100 doses of the unit in the packages of blister (10 cards of 10 tablets each one).

Give in a tight package. Store in the temperature of the control room (1ö 30oC, (5ø to 8õF).

(Ortho-McNeil-McNeil Phamacist, 3/95, 633-19-227-1)

(95/3/3)

HOW HE IS PROVIDED - EQUIVALENT NONCAVAILABLE:

Tablet, - oral - magnesium without covering 50

100 $60,00 ULTRAM, Mc Neil Pharm 00045-0659-60

100 $66,00 ULTRAM, U.D., Mc Neil Pharm 00045-0659-10

Text book of the nurse office
Text book of the nurse office
Text book of the nurse office
Text book of the nurse office
Tramadol against venlafaxine
Tramadol like antidepressant
Tramadol: analysis of risk/benefit
Tramadol against buprenorphine
Depression, opioids and the HPA
Preparation of the launching of Tramadol/sustained
Pharmacokinetics and pharmacodynamics
Morphine: an humor-illumination elegant-drug?
Tramadol, depression and disease of Parkinson

CARETAKER
HedWeb
Cannabis.net
Investigation of BLTC
Pharmacies Coast outside
Parai'so-Ingenieri'a
Utópica Pharmacology
The Hedonistic Imperative
When he is the best one to take the cocaine from the crack?